logo

MRK

Merck·NYSE
--
--(--)
--
--(--)

MRK fundamentals

Merck (MRK) released its earnings on Feb 3, 2026: revenue was 16.40B (YoY +4.97%), beat estimates; EPS was 2.04 (YoY +18.60%), beat estimates.
Revenue / YoY
16.40B
+4.97%
EPS / YoY
2.04
+18.60%
Report date
Feb 3, 2026
MRK Earnings Call Summary for Q4,2025
  • Revenue Growth: Q4 2025 revenue $16.4B (+5% YoY), driven by KEYTRUDA (+5%), new launches (WINREVAIR, OHTUVAYRE), and Animal Health (+6%).
  • Pipeline Momentum: $70B+ pipeline by mid-2030s includes enlicitide ($5B+), MK-1406 ($5B+), and HIV组合疗法. 2026 guidance: $65.5-67B revenue (+1-3%).
  • Strategic Acquisitions: $9B Cidara charge for MK-1406; Verona Pharma acquisition expands respiratory portfolio.
  • Clinical Milestones: Enlicitide Phase III data shows LDL-C reduction; sac-TMT in 16 Phase III trials; HIV dual regimen non-inferior to Biktarvy.
EPS
Revenue

Revenue & Expenses

MRK has released its 2025 Q4 earnings report, with revenue of 16.40B, reflecting a YoY change of 4.97%, and net profit of 2.96B, showing a YoY change of -20.91%. The Sankey diagram below clearly presents MRK's revenue sources and cost distribution.

Key Indicators

Merck (MRK) key financial stats and ratios, covering profitability, financial health, and leverage.
Merck (MRK)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Merck (MRK)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Merck (MRK)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Merck (MRK) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Merck (MRK) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield